Pharma Giants Forge Strategic Alliances Amid Surging Deal Values

　　【Pharmaceutical Network Industry DynamicsIn recent years, driven by the transformation of the pharmaceuticals industry and to address increasing market challenges, pharmaceutical companies have been accelerating the research and development as well as commercialization of innovative drugs, leading to more frequent collaborations between them. Notably, leading companies prefer to form powerful alliances. Recently, a wave of partnerships has emerged among large multinational pharmaceutical corporations.
 

On May 4, Genesis Therapeutics announced a collaboration with Eli Lilly to discover innovative therapies for up to five targets across multiple therapeutic areas using Genesis’ artificial intelligence (AI) drug discovery platform. Public data shows that Genesis’ molecular AI platform integrates 3D structure-aware deep neural networks, novel molecular simulation methods, and a highly scalable molecular generation engine. The company’s technology is particularly well-suited for targeting previously undruggable or data-limited targets.
 

According to the agreement, scientists from Genesis and Eli Lilly will jointly use Genesis' AI drug discovery platform to develop potential "first-in-class" and "best-in-class" candidate drugs for three targets. Genesis will receive upfront and milestone payments totaling up to $670 million, while Eli Lilly has the option to add two additional targets.
 

On the same day, Amphista Therapeutics announced that it had reached research and development collaborations with Bristol Myers Squibb and Merck, respectively. Based on its protein degrader discovery platform, the company will develop a new generation of protein degradation therapies. It is reported that these two companies will bring $2.3 billion in revenue to this British biotechnology firm.
 

Specifically, in the collaboration with Merck, the two companies will develop small-molecule protein degraders for three targets in the fields of oncology and immunology. Amphista will receive $44 million in upfront cash and is eligible for up to $1 billion in milestone payments. In the partnership with Bristol-Myers Squibb (BMS), the two parties will collaborate to discover and develop small-molecule protein degraders, with Amphista receiving $30 million upfront and being eligible for up to $1.25 billion in milestone payments. BMS already has several protein degradation therapies in its pipeline, including CC-92480, which has entered Phase I clinical trials.
 

On May 3, Gilead Sciences and DRAGONFLY Therapeutics, Inc. jointly announced that they had reached a research and development collaboration to advance a series of DRAGONFLY’s immunotherapies based on innovative natural killer (NK) cell engagers for oncology and inflammatory indications. NK cell engagers represent an innovative mechanism of action with the potential to treat a wide range of cancer types.
 

The agreement shows that Gilead will obtain the development rights to DF7001, an investigational immunotherapy targeting 5T4, and gain the option to acquire research and development rights for other candidate therapies based on Dragonfly's TriNKET technology platform. Gilead will pay $300 million upfront, and Dragonfly is also eligible to receive various milestone payments.
 

In addition to the aforementioned companies, since the beginning of this year, AstraZeneca, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico Medicine, Biocytogen, BeiGene, and other pharmaceutical companies in and outside of China have successively announced new and diversified cooperation updates.
 

Analysis suggests that this is mainly due to the impact of changes in the pharmaceuticals industry. In order to address an increasing number of market challenges, accelerate the development of new drugs, develop combination therapies, and enhance competitiveness, a large number of pharmaceutical companies both in China and abroad will achieve complementary advantages through strategic collaborations. This will allow them to better advance research and development and speed up the commercialization of products. In the future, this will also benefit more patients.
 

Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.